Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr. […]

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

WAYNE, PA., Oct. 15, 2024 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced two poster presentations at the upcoming 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference,

Watsco Schedules Third Quarter Earnings Conference Call on Wednesday, October 23, 2024

MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced today that it will host a conference call to discuss its 2024 third quarter financial results on Wednesday, October 23, 2024 at 10:00 a.m. (EDT). Prepared remarks regarding the results will be followed by a question-and-answer session with the senior management team. The

Bombardier to Report Third Quarter Financial Results on November 7, 2024

MONTRÉAL, Oct. 15, 2024 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the third quarter of 2024 on November 7, 2024. Financial results for the third quarter 2024 Eric Martel, President and Chief Executive Officer, Bombardier, and Bart Demosky, Executive Vice President and Chief Financial Officer, Bombardier, will present the financial

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further

Allied Announces Commitment to Set Science-Based Emissions Reduction Targets and Announces 2024 GRESB Score

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — Allied Properties Real Estate Investment Trust (“Allied”) (TSX:AP.UN) announced today that it has committed to set near- and long-term greenhouse gas (“GHG”) emissions reduction targets, in line with the Science Based Targets initiative (“SBTi”) and a 1.5°C decarbonization pathway. These targets will apply to both the rental and

Sapiens Decision Launches Solution to Boost Decision Underwriting Efficiency and Profitability for P&C

Sapiens Decision Underwriting Accelerator elevates straight-through processing and reduces reliance on IT by up to 90% Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced the release of Sapiens Decision Underwriting Accelerator, a cutting-edge solution designed to enhance underwriting efficiency and significantly improve straight-through

MRC Global Announces Actions to Strengthen Its Capital Structure

Agrees to Repurchase Preferred Stock Launches Term Loan B Financing to Fund Repurchase Pursues Amendment to ABL Facility to Extend Maturity Provides Preliminary Third Quarter 2024 Financial Results HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) — MRC Global Inc. (NYSE: MRC) announced today that it has agreed to repurchase all 363,000 shares of its 6.50% Series

Telsec Property Corporation Rejects the “Take Under” offer for the Melcor REIT by Melcor Developments Limited and urges all Unit Holders to vote NO. Unit Price Tender Offer is far below the Net Asset Value

Telsec Property Corporation (“Telsec”), through affiliated entities, is an owner of approximately 2,830,000 million Trust Units of Melcor Real Estate Investment Trust (TSX: MR.UN) (the “REIT”) or approximately 21.84% of the publicly traded units and 9.7% ownership of the REIT. We have been a very patient Unitholder in the Melcor REIT for 8 years feeling

/C O R R E C T I O N — Zinnov/

In the news release, Zinnov estimates Digital and Engineering R&D Spends will surge 1.4X to touch USD 3 Trillion by 2027, issued 07-Oct-2024 by Zinnov over PR Newswire, we are advised by the company that Onward Group and Gopherslab should read as Onward Tech and Gophers Lab as originally issued inadvertently. The complete, corrected release

Scroll to Top